retatrutide glp-1 gip glucagon triple agonist A review of an investigational drug retatrutide, a novel agent for the treatment of obesity | European Journal of Clinical Pharmacology Retatrutide online: complete guide to

This might be because there are no data available with GLP -1 RAs in pregnant women to inform us of the associated risks

It often leads to reduced cravings for sugary, sweet, and similar foods

When a novel therapy shows real promise of helping patients and garnering FDA approval, it is not long before other companies launch their own efforts

Monitoring headache severity, timing, and associated symptomssuch as nausea or dizzinesshelps distinguish GLP-1related headaches from other causes and informs whether continued titration is appropriate

Over time, this can affect every part of the body, such as our bones, muscles and nervous system

doi: 10.1093/cercor/bhp169 123 NakamuraYKoikeS